Skip to main content

Table 2 Proteinuria reduction and treatment response in patients with FSGS treated with Acthar gel

From: Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series

Patient

Previous IST/CT

Concurrent medications

Serum albumin

SCr

Proteinuria

Treatment response

Pre-Acthar

Pre-Acthar

Pre-Acthar

Post-Acthar % change (mg/dL)

Post-Acthar % change (mg/d)

 

Post-Acthar (g/dL)

 

1

Prednisone, cyclosporine, cyclophosphamide

ACEI, cyclosporine

1.7

1.7

6700

Partial remission

2.7

1.6

3300

−5.9

−50.7

2

Prednisone, cyclosporine, MMF, tacrolimus, rituximab

Tacrolimus, MMF

3.0

0.9

5800

Partial remission

3.4

0.8

2016

−11.1

−65.2

3

Prednisone

None

3.2

2.2

5000

Clinical response

3.8

2.2

3422

0

−31.6

4

None

ARB

3.9

4.8

7900

Partial remission

4.0

6.7

2300

39.6

−70.9

5

None

ARB

3.2

3.2

3840

Early termination

NA

NA

NA

NA

NA

6

Prednisone, cyclosporine

ARB, ACEI cyclosporine

2.8

3.0

7500

Partial remission

3.9

2.5

1768

−16.7

−76.4

7

Prednisone, cyclosporine

ARB, ACEI cyclosporine

3.1

1.1

5280

Clinical response

3.6

1.3

3560

18.2

−32.6

8

None

ACEI

NA

1.2

4000

Partial remission

NA

1.1

765

−8.3

−80.9

9

Prednisolone, methotrexate

ACEI, prednisolone

3.1

1.6

9306

Partial remission

3.3

2.0

2773

25.0

−70.2

10

MMF

ACEI, MMF

NA

4.4

2830

Clinical response

4.0

5.0

1629

13.6

−42.4

11

Prednisone

ARB

3.5

2.4

3500

Partial remission

3.7

3.1

750

29.2

−78.6

12

Prednisone

ACEI

3.8

1.5

5700

Early termination (Partial remission)

4.0

1.2

1500a

−20.0

−73.7

13

Prednisone, cyclosporine

None

3.2

3.1

3250

Clinical response

3.5

4.1

2073

32.3

−36.2

14

Prednisone, cyclosporine

ACEI

3.7

2.5

2500

Partial remission

NA

3.0

1246

20.0

−50.2

15

Prednisone, cyclosporine, MMF

ACEI

3.6

1.4

4070

No response

3.3

1.5

3930

7.1

−3.4

  1. Abbreviations: ACEI angiotensin-converting-enzyme inhibitor, ARB angiotensin II receptor blockers, CT cytotoxic therapy, FSGS idiopathic focal segmental glomerulosclerosis, IST immunosuppressive therapy, MMF mycophenolate mofetil, NA not available
  2. aPost-Acthar gel assessment occurred following 4 months of treatment